doxazosin has been researched along with Parkinson Disease in 2 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate predictors of the response to doxazosin, a selective alpha-adrenoceptor antagonist, when used for the treatment of lower urinary tract symptoms in men with Parkinson's disease." | 5.19 | Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease. ( Barbosa, ER; Bessa Junior, Jd; Bruschini, H; Gomes, CM; Lopes, RI; Nitti, VW; Sallem, FS; Sammour, ZM; Srougi, M; Trigo-Rocha, FE, 2014) |
| " Additional dose-response analyses were carried out." | 1.62 | Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. ( Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simmering, JE | 1 |
| Welsh, MJ | 1 |
| Liu, L | 1 |
| Narayanan, NS | 1 |
| Pottegård, A | 1 |
| Gomes, CM | 1 |
| Sammour, ZM | 1 |
| Bessa Junior, Jd | 1 |
| Barbosa, ER | 1 |
| Lopes, RI | 1 |
| Sallem, FS | 1 |
| Trigo-Rocha, FE | 1 |
| Bruschini, H | 1 |
| Nitti, VW | 1 |
| Srougi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for doxazosin and Parkinson Disease
| Article | Year |
|---|---|
Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Antiparkinson Agents; Doxazosin; Humans; Lower | 2014 |
1 other study available for doxazosin and Parkinson Disease
| Article | Year |
|---|---|
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, | 2021 |